Search results for "From ACP Journal Club"
In T2DM with obesity, time-restricted eating increased weight loss and reduced HbA1c level at 6 mo
The small trial comparing time-restricted eating and calorie restriction with control was adequately powered to inform clinical practice, but larger trials with longer follow-up should be done to confirm the results, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/02/09/6.htm
9 Feb 2024
In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin
A new study provides some reassurance to patients who unintentionally become pregnant while taking diabetes drugs but should be interpreted with caution because the number of infants exposed was low and only pregnancies resulting in live births were included, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/04/12/7.htm
12 Apr 2024
In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y
An ACP Journal Club commentary noted that it's unknown whether lower-risk and younger statin-intolerant patients would derive the degree of benefit from bempedoic acid found in this study, since the industry-funded trial enrolled only high-risk and older patients.
https://diabetes.acponline.org/archives/2024/04/12/8.htm
12 Apr 2024
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Based on this and previous trials, low-dose colchicine should be considered as anti-inflammatory therapy for secondary prevention after myocardial infarction (MI) in patients at high risk for cardiovascular (CV) events, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2024/05/10/7.htm
10 May 2024
In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary
A recent systematic review of the beneficial and harmful effects of 15 glucagon-like peptide-1 receptor agonists (GLP-1 RAs) should be helpful to clinicians and suggests which drugs are likely to dominate the market in the next few years, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/05/10/8.htm
10 May 2024